TLSI Stock — TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc. (TLSI)

Updated October 16, 2026.

TLSI is a Stock. Total return is -77.3% over the past 28.8 years, 1265.4 points behind SPY at 1188.1%.

TriSalus Life Sciences develops drug delivery technology and immuno-oncology therapeutics focused on treating liver and pancreatic cancers, with products including its TriNav infusion system for transarterial procedures and investigational therapies in clinical trials. The company does not currently distribute to shareholders. TriSalus is an early-stage biopharmaceutical company dependent on clinical development progress and commercialization success, appealing primarily to investors with high risk tolerance seeking exposure to oncology innovation.

TLSI performance versus SPY

Price and return data through 2026-10-16.

Total return is -77.3% over the past 28.8 years, 1265.4 points behind SPY at 1188.1%. Over the past year its total return — price change plus distributions reinvested — is -23.6%. Its deepest 1-year drawdown was 66.4%.

TLSI key facts

Asset type

Stock

Asset class

Equity

Inception date

12/31/1997

Distribution frequency

None

Last close

$3.63 (as of 2026-10-16)

Market cap

$223,515,798

Average volume

253519.0

Beta

0.469

Payout ratio

0.0%

EPS

$-1.18

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

TLSI risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 66.4%.

Who may consider TLSI — and who may not

It is a weaker fit for investors who need monthly cash flow (TLSI does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on TLSI

• All tickers starting with T

Tagged: Healthcare.

Frequently asked questions